Veru Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
24.7%projected annual EPS growth
Analyst Coverage
2analysts covering
FY EPS (est.)
-$1.20next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Phase 2b PLATEAU Trial 36-Week Interim Analysis | 31 Mar 2027 |
Monitoring Framework
Key Performance Indicators
Phase 2b PLATEAU Clinical Trial Enrollment Progress QuarterlyTarget: Complete enrollment of approximately 200 patients
Cash and Cash Equivalents Balance Quarterly27.6MTarget: Sufficient to fund operations beyond the Q1 calendar year 2027 interim analysis
Quarterly Net Loss from Continuing Operations Quarterly-2.7MTarget: Narrowing of losses through disciplined cost management
Watch Items
- Interim analysis of Phase 2b PLATEAU clinical trialTrigger: 36-week data readout on lean body mass and fat massAction: Evaluate efficacy of enobosarm 3mg in combination with semaglutide to support Phase 3 planning
- Cash runway and capital resourcesTrigger: Cash balance falling below $15 millionAction: Assess potential non-dilutive financing, partnerships, or utilization of the $200 million shelf registration
- Regulatory alignment with the FDATrigger: FDA feedback on Phase 3 trial design and endpointsAction: Finalize clinical protocols for enobosarm modified-release formulation
Research as of 20 Jun 2026